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Abstract: In the broadest context, biological markers, or biomarkers, are molecules that
characterize a biological system or process. In the setting of cardiovascular disease, a number
of biomarkers have become an integral part of diagnostic and risk stratification strategies. In
this review, we will discuss classic and emerging biomarkers of cardiovascular disease and
the role of these biomarkers in the diagnosis and prognosis of elderly patients presenting with
acute myocardial infarction.
Keywords: cardiovascular disease, biological markers, diagnosis, prognosis

Acute coronary syndromes in the elderly
Ischemic heart disease (coronary artery disease, angina pectoris, and myocardial
infarction) is commonly encountered in the current medical era. Data from the
2007–2010 National Health and Nutrition Examination Survey suggests 6.4% of all
Americans .20 years old (15.4 million adults) have some form of ischemic heart
disease. Not surprisingly, the prevalence of symptomatic ischemic heart disease
increases with age. United States census data for 2012 revealed a total population of
313 million persons, with 61 million (∼20%) being categorized as elderly ($60 years).1
Of these individuals, about 21% of men and 11% of women aged 60–79 years
have ischemic heart disease; the numbers jump to 35% of men and 19% of women
aged $80 years. In the United States, 180,000 men and 210,000 women over the age
of 75 suffer an acute myocardial infarction (AMI) or die from coronary heart disease
every year. The estimated direct and indirect cost of ischemic heart disease was $195.2
billion in 2009. This number is projected to increase ∼100% from 2013 to 2030.2

Biomarkers of myocardial necrosis
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In the broadest context, biological markers, or biomarkers, are molecules that characterize a biological system or process. They are measured in a variety of situations and
may indicate normal physiology, identify pathologic states, or be used to monitor a
therapeutic response. Ideally, biomarkers affect therapy by identifying patients likely
to benefit from a therapeutic intervention or in whom a more aggressive diagnostic
strategy should be undertaken. In the setting of cardiovascular disease (CVD), biomarkers, particularly cardiac troponins (cTn) have become an integral part of diagnostic
strategies. Other biomarkers alone or in combination have been shown to identify
patients at high risk for subsequent adverse outcomes, but have not been shown to
predict a response to a particular therapeutic strategy.
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Traditionally, creatinine kinase (CK), lactate dehydrogenase,
and aspartate aminotransferase were used to evaluate for myocardial damage among patients presenting with chest pain.
While sensitive for detecting cellular death, these biomarkers
lacked specificity for myocardial injury. Later, the myocardial
band (MB) isoform of CK (CK-MB) and serum myoglobin
levels were utilized to improve specificity for cardiac damage
and reduce the time to diagnosis (Figure 1). In the last two
decades, the measurement of serum troponin level has become
the predominant biomarker for the detection of myocardial
necrosis. In this review, we will discuss the evolution of troponin as the quintessential biomarker for the diagnosis of AMI.

We will also discuss newer biomarkers being evaluated as part
of a multimarker approach for the diagnosis of AMI.

Serum troponin
and the diagnosis of AMI
Cardiac troponin I (cTnT) and troponin I (cTnI) are both
structural proteins found in the contractile apparatus of
cardiac myocytes (Figure 1). Both of these molecules are
coded by single genes that are not expressed outside of the
cardiac myocyte. In the myocyte, troponin is found in two
“pools”; the majority (∼95%) is bound to actin filaments in
the sarcomere and is released into the systemic circulation
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Figure 1 The cardiac sarcomere showing the sites at which troponin T and I are active.
Notes: The temporal release pattern of the classic biomarkers of myocardial infarction including cTnT, cTnI, CK-MB, myoglobin, and LD1. Reprinted with permission
from Lippincott Williams & Wilkins/Wolters Kluwer Health: Anesthesiology. Archan S, Fleisher LA. From creatine kinase-MB to troponin: the adoption of a new standard.
112(4):1005–1012.50 Copyright © 2010 Wolters Kluwer Health. Promotional and commercial use of the material in print, digital or mobile device format is prohibited without
the permission from the publisher Lippincott Williams & Wilkins. Please contact journalpermissions@lww.com for further information.
Abbreviations: AMI, acute myocardial infarction; CK-MB, creatine kinase myocardial band; cTnI, cardiac troponin I; cTnT, cardiac troponin T; LD1, lactate dehydrogenase 1.
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when the myocyte dies. The “cytoplasmic” or “early appearing” pool of troponin is unbound and can be released into the
circulation in the absence of cell death.3 Myocyte damage
and cell death induces release of the “early pool” of cTn followed by release of the bound troponin. Levels usually peak
12–24 hours after injury, but may be present in circulation
for weeks following a large AMI.4
Early studies identified troponin as a more sensitive
marker of AMI than CK-MB.5 Subsequently, “troponin
positive”, CK-MB “negative” patients were found to be at
substantial short-term risk for recurrent myocardial infarction
and mortality.6 Most importantly, troponin elevation alone
was found to identify patients likely to benefit from intensive
antiplatelet therapy or an early invasive management strategy.7,8 Eventually, elevated troponin levels were included in
risk stratification schemes such as the TIMI-Risk Score and
the GRACE-Risk Score.9,10

The universal diagnosis of AMI
The importance of cTn in the diagnosis and management of
AMI was recently underscored by the development of a new
“definition” of myocardial infarction. This universal definition of myocardial infarction is based on the detection of a
rise and fall in troponin, with at least one value greater than
the 99th percentile of the upper reference limit (URL) for
the assay. This biomarker elevation must be accompanied
with at least one of the following: symptoms suggestive of
ischemia, new or presumed new ST changes of left bundle
branch block, pathological Q-waves, imaging that indicates
the loss of viable myocardium or a new regional wall motion
abnormality, or identification of intracoronary thrombus at
autopsy.11 With the advent and, now, routine use of biomarkers, the definition of an AMI has been transformed from a
clinical diagnosis supported by electrocardiogram findings
and biomarkers to a biomarker measurement supported by
electrocardiogram and clinical findings.12

Troponin assays
There are several commercially available cTnI assays,
but cTnT assays are produced by a single manufacturer.
These assays are based on the affinity of an antibody for an
epitope on the troponin molecule and vary significantly with
respect to clinical performance, making it essential to understand the test characteristics of the specific product being
used. To date, there is no agreement regarding the reference
population used to characterize a particular assay; therefore,
variability with respect to age, sex, and ethnicity is to be
expected. Ideally, each hospital laboratory would perform
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reference testing independently to determine the precision
of the assay and local “cutoff ” points. This is generally not
possible, and so a reliance on published values for reference
limits and reliability exists.
In general, there are three characteristics of troponin
assays that should be considered. The point at which a
troponin concentration is deemed abnormal or “elevated”
is based on a determination of the 99th percentile URL for
a given assay. Using this definition, the risk that a healthy
person, selected at random from the general population, has
an abnormal troponin level is 0.01 (1%). The coefficient of
variability (CV) is a measure of the imprecision of a laboratory test if the same sample were repeatedly analyzed. With
respect to serum troponin assays, a CV of ,10% is considered ideal, and an assay with a CV of .20% should not be
utilized, in general.11 A CV between 10% and 20% may be
of use, but may be associated with a few more misclassifications at low troponin concentrations.13 An ideal assay would
then be characterized by a CV of ,10% at the 99th percentile
URL. Unfortunately, contemporary troponin assays are at the
limits of their detection at low troponin levels and are often
unable to deliver precise measurements at or below the 99th
percentile URL (CV .20%). In such situations, it has been
recommended that a cutoff be set at the lowest point that can
be measured with a CV of ,10%.14 Regardless, a solitary
elevation in cTnI or cTnT is considered insufficient for
the diagnosis of AMI. In most cases, serial measurements
drawn 3–6 hours apart are performed, and the diagnosis of
AMI is established when a rise and fall in the level of cTnI
or cTnT is detected.11

Troponin elevations outside
the setting of AMI
It is important to note that the evidence substantiating the
role of troponin in the diagnosis of AMI arises from studies
in which the subjects had a relatively high pretest probability
of having coronary artery disease and AMI. As with any
diagnostic test, the reliability of the test decreases considerably when used in situations in which AMI is unlikely. At
the time of development, it was hoped that elevations in cTn
would be sensitive, but perhaps more importantly, exquisitely
specific for myocardial injury.15 Unfortunately, experience
with these assays has demonstrated numerous situations in
which “elevated” cTn levels do not signal AMI. Specifically,
it is known that patients with renal failure or chronic systolic
or diastolic heart failure (HF) can have a persistently elevated
cTn.16–18 Additionally, it has been noted that an elevated cTn
can be associated with other life-threatening conditions such as
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aortic dissection, pulmonary embolism, and sepsis.19–21 Despite
this lack of specificity, the test is frequently ordered. In one
analysis, a serum troponin level was ordered in 48% of patients
presenting to an emergency department, only 29% of whom
were admitted to “rule out” a myocardial infarction.22 Thus, it
has become common for a cardiologist to be asked to evaluate
a patient simply because of “an elevated troponin”.23,24

Troponin elevations in the elderly
The current generation of troponin assays is poorly studied
among elderly patients. The studies that established troponin
as the diagnostic standard for AMI enrolled relatively young
patients with a high pretest probability of AMI.6 Subsequent
studies have found troponin elevations in “apparently healthy”
subjects, especially those that are elderly. For example, in
the Prospective Investigation of the Vasculature in Uppsala
Seniors (PIVAS) study, 1,005 persons 70 years of age were
evaluated for the presence of elevated cTnI levels. Using
an assay with a lower limit of detection of 0.006 µg/L and
“abnormal” cutoff value of 0.01 µg/L, the authors found that
21.8% of these patients had an elevated cTnI level. Predictors
of elevated cTnI included the male sex, cardiac risk factors,
and impaired left ventricular systolic function.25 In contrast,
in the Dallas Heart Study (DHS), 3,557 patients aged
30–65 years underwent a test for serum troponin using a cTnT
assay with a lower detection limit of 0.01 µg/L. A detectable
troponin level was found in only 1% of these younger subjects
(0.7%; confidence interval 0.3%–1.1%).26 Thus, the diagnostic
characteristics of the traditional troponin assays among elderly
subjects remains to be definitively determined.

Multiple biomarkers
for the diagnosis of AMI
The increasing sensitivity of troponin makes it unlikely
another marker of myocardial necrosis will add considerably
to diagnostic or prognostic algorithms for AMI. However,
there are still patients in whom troponin levels at presentation
are undetectable and who proceed to be diagnosed with an
AMI. Recently, diagnostic strategies using a combination of
biomarkers have been evaluated in hope of identifying high
risk patients with chest pain. The combination of troponin
and a biomarker that does not arise from myocardial necrosis
but by a different mechanism such as myocardial stretch,
inflammation, or stress is appealing.

Natriuretic peptides
Brain natriuretic peptide (BNP) is a natriuretic hormone produced by myocytes and was initially identified in the brain.
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A prohormone is released in response to increased wall
tension or myocardial stretch. Cleavage of the prohormone
in circulation releases BNP and the more stable N-terminal
fragment (NT-proBNP). Plasma concentrations of both of
these hormones are elevated in patients with left ventricular
dysfunction (systolic or diastolic) and are frequently used
to aid in the diagnosis of clinical HF.27 The measurement
of NT-proBNP and BNP levels have become commonplace
in the setting of HF. It has become evident, however, that
NT-proBNP and BNP levels are also elevated in a variety
of other situations associated with myocardial dysfunction, such as pulmonary embolism, sepsis, and myocardial
infarction.28–30

BNP and NT-proBNP in the elderly
Plasma concentrations of BNP and NT-proBNP increase with
increasing age. In fact, age appears to be the most important
independent variable in explaining plasma levels of BNP and
NT-proBNP.31,32 The reason for this increase is not entirely
clear. Initial investigations suggested cardiac structural
alterations (increased left ventricular mass, increased left
atrial volume) and reduced renal clearance of the natriuretic
peptides with aging. However, when BNP was studied in a
population of more than 700 normal subjects in sinus rhythm
without cardiovascular disease, renal disease, pulmonary
disease, or diabetes, on no cardiovascular medications, and
with normal cardiac function, age was still an independent
predictor of BNP levels.32

C-reactive protein
Inflammation plays a central role in the development of
atherosclerosis. C-reative protein (CRP) is a marker of
inflammation. Elevations in CRP, especially when measured
using highly sensitive assays (hs-CRP) have been shown to
predict the presence of coronary disease among apparently
healthy subjects and to predict adverse events in the setting
of AMI.33,34

Multimarker strategies
The potential of serum cTnI, BNP, and hs-CRP to predict
outcomes in AMI was established by evaluating blood
samples collected from a subset of patients enrolled in a large
clinical trial. Samples were drawn in 450 patients within
72 hours of presentation with AMI and sent to a core lab
for analysis. Multivariable analysis indicated each of these
biomarkers was an independent predictor of subsequent
adverse outcomes including death, recurrent myocardial
infarction, and the development of HF. A scoring system
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was developed that reflected the number of biomarkers that
were elevated. The risk of mortality, recurrent myocardial
infarction, or HF at 30 days increased in proportion to the
number of biomarkers that were elevated. This scoring system was then validated in a larger cohort of patients enrolled
in another clinical trial.35
The prognostic utility of NT-proBNP, hs-CRP, and cTnT
and several other candidate biomarkers has been studied in
a group of patients presenting with chest pain. Both NTproBNP and cTnT, but not hs-CRP, emerged as independent
predictors of adverse events in the year following presentation (Figure 2). An elevated NT-proBNP ($1,371 ng/L) was

associated with an adjusted odds ratio of 2.7 for death or AMI
at 1 year. When the concentration of both NT-proBNP and
cTnT exceeded the cutoff values, the risk of death or AMI
at 1 year was 11.9% compared with 1.4% among patients in
whom neither biomarker was elevated.36

Future perspectives – emerging
biomarkers
The next generation of troponin assays
Newer troponin assays promise to be significantly more
sensitive. These newer assays are in use in Europe and await
approval from the US Food and Drug Administration before
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Figure 2 Kaplan–Meier curves demonstrating survival from death or myocardial infarction stratified by the level of cTnT ($0.03 µg/L) or NT-proBNP (,1,371 ng/L).
Note: Reprinted from Am J Cardiol 103(1), McCann CJ, Glover BM, Menown IB, et al. Prognostic value of a multimarker approach for patients presenting to hospital with
acute chest pain, pages 22–28.36 Copyright © 2009 with permission from Elsevier.
Abbreviations: cTnT, cardiac troponin T; NT-proBNP, N-terminal prohormone of brain natriuretic peptide.
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they enter the market in the United States. They have been
given the name “high-sensitivity” troponin (hs-cTn) assays,
as they detect troponin at concentrations tenfold lower than
the currently utilized assays. That said, these assays are based
on the same biochemistry as traditional troponin assays and
are likely just the next, rather than the final, step along the
path of improving sensitivity. The increased sensitivity will
force providers to rethink how these assays are used (Table 1).
For example, simply detecting troponin with these assays
will not be suggestive of myocardial ischemia as there will
be a measurable troponin level in many, if not most, persons
admitted to emergency departments as well as a significant
proportion of the general population.12
In the DHS, the ability of a traditional and highly sensitive cTnT assay to predict adverse events among a cohort
of apparently healthy adults was compared. As noted
above, ∼1% of apparently healthy patients had a detectable
troponin level using a traditional troponin assay. The same

samples were also analyzed using an hs-cTnT assay with
a lower limit of detection of 3.0 ng/L and a 99th percentile
URL of 1.4 ng/L. A detectable serum troponin was noted in
25% of these subjects. Elevated hs-cTnT was independently
associated with all-cause and cardiovascular mortality in a
concentration-dependent manner (Figure 3).37
In emergency departments, hs-cTn measurements promise to change practice patterns. A large study by Reichlin
et al was recently performed in which the effectiveness of
four sensitive cTn assays were evaluated among 718 patients
presenting to the emergency department complaining of
symptoms consistent with AMI. The hs-cTn assays all performed well when compared with a standard troponin assay,
especially among patients presenting within a few hours of
the onset of symptoms. Perhaps as importantly, the negative
predictive value of these assays was quite high. In fact, when
the 99th percentile URL was used as a cutoff, the negative
predictive value was 97%–99%.38

Table 1 A comparison of contemporary and highly sensitive troponin assays
Characteristic

Current assays

High sensitivity assays

General

There is a variety of available troponin assays
with unique test characteristics
• The test characteristics and cutoff values will
vary from assay to assay
• Elevated levels uncommon in “apparently
healthy adults”

Diagnosis of AMI

Elevated troponin levels in the appropriate clinical
setting are required for the diagnosis of AMI
• Serial measurements to detect a rise and fall
in troponin concentration will likely remain an
important part in the diagnosis of AMI

Exclusion of AMI

The absence of a measurable troponin on a single
blood draw is insufficient to exclude AMI
Troponin levels may be elevated in a variety of
pathological states, some of which constitute
medical emergencies
• Aortic dissection
• Pulmonary embolism
• Shock
• Heart failure
• Chronic renal insufficiency
Elevated serum troponin levels appear to be
associated with a poor prognosis
• Especially among hospitalized patients

There is a variety of available troponin assays with
unique test characteristics
• Ten times more sensitive than conventional assays
• Elevated levels common in “apparently healthy”
adults
• “Cutoff” values will vary significantly across
reference populations and with age
Elevated troponin levels in the appropriate clinical
setting are required for the diagnosis of AMI
• Significantly improved sensitivity, which translates to
earlier detection
• Reduced specificity
• Serial measurements may still be required
• The absence of a measurable troponin will likely
exclude AMI
Troponin levels may be elevated in a variety of
pathological states, some of which constitute medical
emergencies
• Aortic dissection
• Pulmonary embolism
• Shock
• Heart failure
• Chronic renal insufficiency
Elevated serum troponin levels appear to be associated
with a poor prognosis
• May prove true among “apparently healthy
outpatients”
Limitations
• Better studied in the elderly
• Troponin levels “measurable” in the majority of
elderly patients
• Age specific “cutoff” values may be needed

Non-cardiac disease

Prognosis

Pitfalls associated with the
elderly

Limitations
• Few studies evaluate an elderly population

Note: Data from Mohammed and Januzzi,51 and Korley and Jaffe.52
Abbreviation: AMI, acute myocardial infarction.
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Figure 3 Cardiovascular disease mortality among a group of community-dwelling subjects enrolled in the Dallas Heart Study.
Notes: P,0.001 for all between-group comparisons by the log-rank test. Reproduced from de Lemos JA, Drazner MH, Omland T, et al. Association of troponin T detected
with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA. 2010;304(22):2503–2512.37 Copyright © 2010 American Medical
Association. All rights reserved.
Abbreviation: cTnT, cardiac troponin T.

High sensitivity cTn assays
and the elderly
High sensitivity cTn assays will detect troponin in a substantial number of asymptomatic elderly persons. In the DHS,
age was found to be an independent predictor of a measurable
hs-cTnT among asymptomatic adults.37 In an Italian cohort
of community dwelling subjects aged 65–84 years, circulating levels of hs-cTnT were detected in 18% of the females
and 41% of the males. Correlation with echocardiographic
data indicated an association between left ventricular mass,
mid-wall fractional shortening, and diastolic dysfunction.39
Eggers et al evaluated troponin in 940 elderly men, 379 of
whom had an established diagnosis of coronary artery disease
and 561 of whom did not. Using an hs-cTnT assay with a
measureable range (3.0–10,000 ng/L), a detectable troponin
level was found in 92.8% of the patients.40 In another study,
among patients .70 years old, the same group noted that
hs-cTnT levels increased gradually with time and were on
average 45% higher in the same patient after five years.41
Elderly persons presenting to emergency departments
are also commonly found to have measurable troponin levels using hs-cTn assays. Menacer et al42 evaluated troponin
levels among 362 patients presenting to an emergency
department without chest pain or signs of CVD. They used
four hs-cTn assays including an hs-cTnT assay (lower
limit of quantification 13 ng/L) and three different hs-cTnI
assays (lower limit of quantification 32, 40, and 30 ng/L).
As expected, the hs-cTnT proved the most sensitive assay,
detecting a measurable troponin level in 81% of the patients.
Clinical Interventions in Aging 2014:9

The hs-cTnI assays proved less sensitive, detecting troponin
in 15%–56% of this cohort.42 It will be impossible using
high-sensitivity assays to assign a working diagnosis of AMI
using only a serum troponin concentration, especially among
elderly patients.

Copeptin
Arginine vasopressin is released from the neurohypophysis in
response to changes in plasma osmolality and is involved in
osmoregulation and cardiovascular homeostasis. Activation
of the arginine vasopressin system is part of the endogenous
response to stress, such as is encountered in the setting of
AMI. Vasopressin degrades rapidly in circulation and has not
been found to be useful as a biomarker. Instead, copeptin,
the more stable C-terminal fragment of provasopressin,
has emerged as a promising surrogate for vasopressin in
the characterization of the role of the arginine–vasopressin
system in CVD. It has been hypothesized that the addition
of copeptin levels to a diagnostic strategy for AMI might
increase sensitivity and specificity. Reichlin et al43 used a
conventional cTnT assay and a novel copeptin assay to risk
stratify 492 patients presenting to an emergency department
with symptoms suggestive of AMI. They found that copeptin levels were elevated very early in relation to the onset
of symptoms and when compared with cTnT (Figure 4).
Furthermore, when cTnT and copeptin measurements were
evaluated in combination, improved diagnostic sensitivity
for AMI was noted. This was true when the combination
was compared to either assay alone, or the combination of
submit your manuscript | www.dovepress.com
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Figure 4 Copeptin (blue) and troponin T (green) levels at presentation in relation
to the time since the onset of symptoms among patients found to have an acute
myocardial infarction.
Note: Reprinted from J Am Coll Cardiol, 54(1), Reichlin T, Hochholzer W, Stelzig C, et
al, Incremental value of copeptin for rapid rule out of acute myocardial infarction, pages
60–68.43 Copyright © 2009 with permission from Elsevier.

cTnT and CK-MB. Of equal importance, the combination of
cTnT and copeptin was very effective in identifying patients
without AMI (negative predictive value 99.7%).43

Growth-differentiation factor-15
Growth-differentiation factor (GDF)-15 is a member of the
transforming growth factor-B cytokine superfamily. While
GDF-15 is weakly expressed in most tissues under physio
logical conditions, its expression levels increase in response
to pathological stress associated with inflammation or tissue
injury. CVD and AMI are known to be inflammatory states.44
GDF-15 concentrations are elevated in AMI and in chronic
HF. In both cases, these elevations have been associated with
a subsequent increase in mortality.45–48 Recently, GDF-15
was one of several biomarkers evaluated among a group
of patients admitted with chest pain and an “undetectable”
troponin. The study enrolled 1,247 patients, all of whom were
admitted with concern for AMI, but who had undetectable
serum cTnT levels measured by a conventional assay. The
authors found that in this low risk cohort, a GDF-15 level
of .1800 ng/L was associated with an increased risk of death
or myocardial infarction on follow-up.49

Conclusion
The practice of cardiovascular medicine has been forever changed by the ability to measure biomarkers.
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Troponin measurements have become an integral part
of contemporary diagnostic and patient management
algorithms. The current generation of troponin assays has
been shown to better identify patients with AMI who are
at a high risk for adverse events. Additionally, patients
with an elevated troponin seem to benefit from an aggressive therapeutic strategy. The prognostic power of other
biomarkers such as NT-BNP has been established, but no
link between these biomarkers and a therapeutic strategy
has been established. Unfortunately, the studies upon
which these conclusions were based enrolled relatively
few elderly patients.
Research continues to find the next great biomarker for
clinical practice and a few of the emerging candidates, as well
as their potential utility, have been discussed in this paper.
Elderly patients represent the largest portion of cardiovascular patients. There has been an increasing realization for the
need to have algorithms that consider the patient’s age and
other comorbidities rather than a one-size-fits-all approach
to abnormal levels of biomarkers. With the increasing number of available biomarkers, the practice of medicine will
depend more heavily on developing appropriate testing for
all patients.
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